Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Micromet receives milestone payment from Serono
The two phase II clinical trials were evaluating adecatumumab as a single agent for the treatment of patients with metastatic breast cancer and prostate cancer. Micromet and Serono
The two phase II clinical trials were evaluating adecatumumab as a single agent for the treatment of patients with metastatic breast cancer and prostate cancer. Micromet and Serono
For early-stage breast cancer, the standard treatment is a lumpectomy followed by radiation therapy. When to give the chemotherapy has been widely debated among researchers. The outcome for
The Securities and Exchange Commission (SEC) investigation commenced in March 2004 and NeoPharm believes it concerned disclosures regarding the development of two drug candidates. The decision of the
The study was designed to investigate the absolute bioavailability, and the effects of food on the bioavailability, of two oral formulations of CK-1827452. Pharmacokinetic data from this study
The research showed a statistically significant improvement in overall quality of life in as early as three weeks in patients administered the drug. Ulcerative colitis is a form
The $42.6 million Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study directly compared second-generation antipsychotics with older drugs. Total monthly health costs were up to 30% lower for
VCG & Associates is an independent strategic marketing and contract services provider specializing in working with emerging pharmaceutical, biotech and technology companies. New Pharmaceutical Strategies (NPS) provides consulting
“The acquisition of Be-Tabs results in considerable synergies and further strengthens Ranbaxy’s foothold in South Africa. It reinforces our position by expanding our portfolio in a key market
Patients with CCR5-tropic HIV-1 have limited or no approved treatment options due to resistance or intolerance. The treatment maraviroc is in a new class of investigational HIV drugs
In September 2005, Astellas Pharma filed a marketing authorization application for the Eligard six-month product with the German pharmaceutical regulatory authority, BfArM. Eligard is already approved in Germany